Navigating Treatment Evolution in Myelofibrosis: Oncology Pharmacist's Strategies for JAK Inhibitor Optimization

Stream Link 1 PM: https://globalmeet.webcasts.com/starthere.jsp?ei=1682051&tp_key=ddde22664a

Stream Link 8 PM: https://globalmeet.webcasts.com/starthere.jsp?ei=1682054&tp_key=3159d7c281

This activity includes a Powered by Patients™ video interview.

Program Description

Myelofibrosis, a rare and chronic bone marrow disorder, poses significant treatment challenges due to its complex pathology and the risk of disease progression. JAK inhibitors have emerged as a critical component in the frontline and subsequent treatment strategies for myelofibrosis, offering patients substantial relief from symptoms and potential improved survival. However, the optimization of JAK inhibitor therapy requires oncology pharmacists to carefully consider recent guideline updates, clinical indicators of disease progression, and evidence-based strategies for managing transitions between different JAK inhibitors as clinically indicated. This program is designed to equip oncology pharmacists with the essential knowledge and skills to navigate these complexities. By focusing on the latest guidelines, clinical indicators, and supportive care measures, including infection prevention and anemia management, this program will equip oncology pharmacists to ensure the safe and effective utilization of JAK inhibitors, ultimately improving patient outcomes in myelofibrosis treatment.

Target audience: Oncology pharmacists

Type of activity: Application
Release date: September 5, 2024
Expiration date: November 5, 2024

Time to complete activity: 1.0 hour

Learner level: Advanced
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Analyze recent guideline revisions for use of JAK inhibitors in frontline and subsequent treatment strategies for myelofibrosis
• Identify clinical indicators signaling disease progression in patients with myelofibrosis
• Apply evidence-based strategies to manage the safe transition of patients with myelofibrosis from one JAK inhibitor to another
• Ensure comprehensive supportive care measures for patients with myelofibrosis, including infection prevention strategies and targeted interventions for managing anemia

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-0000-24-230-L01-P. The activity is available for CE credit through November 5, 2024.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

James Davis, PharmD, BCOP, has the following financial relationship with a commercial interest to disclose:
Speakers Bureau: Janssen Biotech

The following contributors have no relevant financial relationships with commercial interests to disclose:

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Daphne Davis, PharmD, BCOP; Crissy Wilson; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms